Biophytis jumps after study shows drug candidate improves walking speed

Biophytis SA

02/08/2021 11:59

** U.S.-listed shares of France-based biotech co  BPTS.O 
jump 16.3% to $10 premarket
    ** BPTS says a higher dose of its drug candidate, Sarconeos,
showed a clinically meaningful improvement vs placebo in walking
speed, the main goal of its mid-stage study, in patients with
sarcopenia  urn:newsml:reuters.com:*:nGNX54h7xB
    ** Sarcopenia refers to a progressive loss of skeletal
muscle mass that accompanies aging 
    ** The treatment did not show any effect on handgrip
strength test and on mobility disability, which were the study's
key secondary endpoints - BPTS
    ** Co says no serious adverse events were related to the
treatment, according to the study investigators 
    ** BPTS down 47.9% since its market debut in February

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))